New Chief Scientific Officer

Mogrify Ltd, a regenerative medicine company developing a new class of in vivo reprogramming therapies for diseases with high unmet clinical need, has appointed Dr Jonathan Appleby as CSO.

The experienced drug developer, has been involved in all phases of therapeutic development from discovery to commercialization. He joins Mogrify from the Cell and Gene Therapy Catapult, where he was the Executive Director and Chief Scientific Officer for five years, leading the R&D group focused on ATMP manufacturing processes and analytical development. Prior to that, Appleby was CSO for Cell and Gene Therapy in GSK’s Rare Disease Division. There he led the team that developed StrimvelisTM, the first autologous pediatric CD34+ stem cell gene therapy to be approved for commercial use. He also led the ARSA gene therapy for two years, which was later out-licensed to Orchard Therapeutics and recently approved as LenmeldyTM.

Previously, Appleby was Director and Portfolio Manager at the GSK Center of Excellence for External Drug Development. He graduated in Genetics from the University of Leeds and a PhD from the Department of Biochemistry and Molecular Biology.